Journals Information
Advances in Pharmacology and Pharmacy Vol. 7(4), pp. 63 - 70
DOI: 10.13189/app.2019.070402
Reprint (PDF) (950Kb)
Design and Synthesis of Novel Inhibitor against Ser121 and Val122 Mutations in P53 Cancer Gene
Muhammad Hamza *, Azhar Mahmood , Sajid Khan , Muhammad Rizwan , Anum Munir
Department of Bioinformatics, Government Post Graduate College Mandian, Pakistan
ABSTRACT
The p53 is also known as a tumor suppressor gene, involved in a variety of cellular processes and signaling pathways. p53 mutations are involved in almost all kinds of cancers, and several treatments are available for p53 mutations but have a number of limitations. Still, there is a need for better drugs. Computational methods are emerging and beneficial tools to guide and interpret experiments to fasten the drug design process. This study was undertaken to design a drug that targets p53 Ser121 and Val122 mutations. The compound was identified through virtual screening and several drug-like filters were applied. The identified compound is considered to be non-toxic in nature. ADMET properties and pharmacokinetics of the compound also describe the effectiveness of the compound. The results of this study, suggest that this compound can be used to treat p53 mutations and the compound is synthesized successfully in the lab to determine its adequacy and efficacy. Bis-(4-chlorophenyl)methyl-BLAH compound can be used as a strong inhibitor of p53 Ser 121 and Val 122 mutations.
KEYWORDS
P53, Docking, Mutations, Synthesized, Medicine, Cancer
Cite This Paper in IEEE or APA Citation Styles
(a). IEEE Format:
[1] Muhammad Hamza , Azhar Mahmood , Sajid Khan , Muhammad Rizwan , Anum Munir , "Design and Synthesis of Novel Inhibitor against Ser121 and Val122 Mutations in P53 Cancer Gene," Advances in Pharmacology and Pharmacy, Vol. 7, No. 4, pp. 63 - 70, 2019. DOI: 10.13189/app.2019.070402.
(b). APA Format:
Muhammad Hamza , Azhar Mahmood , Sajid Khan , Muhammad Rizwan , Anum Munir (2019). Design and Synthesis of Novel Inhibitor against Ser121 and Val122 Mutations in P53 Cancer Gene. Advances in Pharmacology and Pharmacy, 7(4), 63 - 70. DOI: 10.13189/app.2019.070402.